Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Rich Pharmaceuticals, Inc. (OTC: RCHA).

Full DD Report for RCHA

You must become a subscriber to view this report.


Recent News from (OTC: RCHA)

Rich Pharmaceuticals Explains How Targeted Immunotherapy Aids in the Treatment and Recovery of AML Patients
BEVERLY HILLS, CA , April 10, 2018 (GLOBE NEWSWIRE) -- Rich Pharmaceuticals, Inc . (OTC:  RCHA ), a Biopharmaceutical Company focused on developing and commercializing innovative therapies in oncology, discusses how its Targeted Immunotherapy works in conjunction with patient’s...
Source: GlobeNewswire
Date: April, 10 2018 07:00
Rich Pharmaceuticals' Study Drug RP-323 (TPA) is a Potential Therapeutic Agent for the Treatment of Hodgkin's Lymphoma
BEVERLY HILLS, CA , March 14, 2018 (GLOBE NEWSWIRE) -- Rich Pharmaceuticals, Inc . (OTC:  RCHA ), a Biopharmaceutical Company focused on developing and commercializing innovative therapies in oncology, announced today the potential for using its drug RP-323 (TPA) in the treatment ...
Source: GlobeNewswire
Date: March, 14 2018 09:45
Rich Pharmaceuticals' Study Drug RP-323 (TPA) Elevates White Blood Cells (WBCs) Which Play a Vital Role Fighting Infections, and in Immunotherapy
BEVERLY HILLS, CA, March 06, 2018 (GLOBE NEWSWIRE) -- Rich Pharmaceuticals, Inc . (OTC: RCHA), is a Biopharmaceutical Company focused on developing and commercializing innovative therapies in oncology using its study drug RP-323 (TPA). Multiple clinical studies have shown a significan...
Source: GlobeNewswire
Date: March, 06 2018 09:45
UPDATE: Rich Pharmaceuticals Retains Experienced Contract Research Organization to Assist with Clinical Trials
BEVERLY HILLS, CA , Dec. 05, 2017 (GLOBE NEWSWIRE) -- Rich Pharmaceuticals, Inc. (OTC PINK: RCHA), a biopharmaceutical Company focused on developing and commercializing innovative therapies in oncology, today announced that it has retained IND 2 Results, LLC, (I2R) Atlanta Georgia, to serv...
Source: GlobeNewswire
Date: December, 05 2017 12:35
Rich Pharmaceuticals Retains Experienced Contact Research Organization to Assist with Clinical Trials
BEVERLY HILLS, CA , Dec. 05, 2017 (GLOBE NEWSWIRE) -- Rich Pharmaceuticals, Inc . (OTC PINK:  RCHA ), a biopharmaceutical Company focused on developing and commercializing innovative therapies in oncology, today announced that it has retained IND 2 Results, LLC, (I2R) Atlanta Georg...
Source: GlobeNewswire
Date: December, 05 2017 10:35

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.00020.00010.00020.00012,043,099
2018-12-130.00010.00010.00020.00017,592,507
2018-12-120.00010.00010.00020.00017,617,500
2018-12-110.00010.00020.00020.000110,514,285
2018-12-100.00010.00010.00010.000150,519

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-14200,0002,043,0999.7891Cover
2018-12-13421,7007,592,5075.5542Cover
2018-12-12975,0007,617,50012.7995Cover
2018-12-113,450,00010,514,28532.8125Cover
2018-12-07164,94010,350,9391.5935Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on RCHA.


About Rich Pharmaceuticals, Inc. (OTC: RCHA)

Logo for Rich Pharmaceuticals, Inc. (OTC: RCHA)

Rich Pharmaceuticals is a biopharmaceutical company that is focused on the development of its lead product, TPA O tetradecanoylphorbol acetate , for the treatment of acute myelogenous leukemia AML in refractory patients. The basis for the interest of the Company to pursue clinical development of TPA in this and possibly other indications is the result of the work of Prof. Richard Chang. He has conducted research on TPA for many years and has become an expert in the characteristics of this molecule. The findings form the scientific basis for the clinical use of TPA.

 

 

 

Current Management

  • Ben Chang / President, CEO, CFO, Treasurer
  • Richard Salvador /
  • Carol A. Salvadore /

Current Share Structure

  • Market Cap: $486,175 - 03/09/2018
  • Issue and Outstanding: 1,215,437,821 - 02/19/2018

 


Recent Filings from (OTC: RCHA)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 23 2018
All other definitive information statements
Filing Type: DEF 14CFiling Source: edgar
Filing Date: March, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018
Preliminary proxy statement containing all other information
Filing Type: PRE 14CFiling Source: edgar
Filing Date: March, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 26 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: February, 20 2018
Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: February, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 06 2018
Withdrawal of registration statement filed under the Securities Act
Filing Type: RWFiling Source: edgar
Filing Date: January, 24 2018

 

 


Daily Technical Chart for (OTC: RCHA)

Daily Technical Chart for (OTC: RCHA)


Stay tuned for daily updates and more on (OTC: RCHA)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: RCHA)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RCHA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of RCHA and does not buy, sell, or trade any shares of RCHA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/